AYTU BIOPHARMA, INC Quarterly Cost of Revenue in USD from Q3 2014 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Aytu Biopharma, Inc quarterly/annual Cost of Revenue history and growth rate from Q3 2014 to Q1 2023.
  • Aytu Biopharma, Inc Cost of Revenue for the quarter ending March 31, 2023 was $9.99M, a 13.2% decline year-over-year.
  • Aytu Biopharma, Inc Cost of Revenue for the twelve months ending March 31, 2023 was $41.2M, a 6.27% decline year-over-year.
  • Aytu Biopharma, Inc annual Cost of Revenue for 2022 was $44.4M, a 21.8% increase from 2021.
  • Aytu Biopharma, Inc annual Cost of Revenue for 2021 was $36.4M, a 340% increase from 2020.
  • Aytu Biopharma, Inc annual Cost of Revenue for 2020 was $8.28M, a 276% increase from 2019.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $41.2M $9.99M -$1.52M -13.2% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $42.7M $8.99M -$1.84M -17% Oct 1, 2022 Dec 31, 2022 10-Q 2023-02-21
Q3 2022 $44.6M $9.62M +$182K +1.93% Jul 1, 2022 Sep 30, 2022 10-Q/A 2023-02-21
Q2 2022 $44.4M $12.6M +$423K +3.47% Apr 1, 2022 Jun 30, 2022 10-K 2022-09-27
Q1 2022 $44M $11.5M -$2.42M -17.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $46.4M $10.8M +$4.58M +73.2% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-21
Q3 2021 $41.8M $9.44M +$5.38M +132% Jul 1, 2021 Sep 30, 2021 10-Q/A 2023-02-21
Q2 2021 $36.4M $12.2M +$6.88M +130% Apr 1, 2021 Jun 30, 2021 10-K 2022-09-27
Q1 2021 $29.5M $13.9M +$11.9M +597% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $17.6M $6.25M +$5.64M +931% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $12M $4.06M +$3.69M +981% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $8.28M $5.3M +$4.65M +717% Apr 1, 2020 Jun 30, 2020 10-K 2021-09-28
Q1 2020 $3.63M $2M +$1.38M +224% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $2.25M $606K +$80.9K +15.4% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-11
Q3 2019 $2.17M $376K -$35.2K -8.58% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $2.2M $649K +$408K +169% Apr 1, 2019 Jun 30, 2019 10-K 2020-10-06
Q1 2019 $1.79M $617K -$520K -45.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $2.31M $525K +$140K +36.3% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 $2.17M $411K +$124K +43.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $2.05M $241K -$109K -31.1% Apr 1, 2018 Jun 30, 2018 10-K 2019-09-26
Q1 2018 $2.16M $1.14M +$812K +250% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 $1.35M $385K -$166K -30.1% Oct 1, 2017 Dec 31, 2017 10-Q/A 2019-05-14
Q3 2017 $1.51M $287K +$95.3K +49.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $1.42M $350K +$14.8K +4.43% Apr 1, 2017 Jun 30, 2017 10-K 2018-09-06
Q1 2017 $1.4M $324K -$16.4K -4.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 $1.42M $551K +$307K +126% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-08
Q3 2016 $1.11M $192K +$155K +414% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $957K $335K +$247K +281% Apr 1, 2016 Jun 30, 2016 10-K 2017-08-31
Q1 2016 $710K $341K +$341K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 $369K $244K +$244K Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 $125K $37.3K +$37.1K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 $88.1K $87.9K Apr 1, 2015 Jun 30, 2015 10-K 2016-09-01
Q1 2015 $0 Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-11
Q4 2014 $0 Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-11
Q3 2014 $225* Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.